Correvio is a private cardiovascular company which manages Aggrastat®. Aggrestat®, in combination with heparin, is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. Correvio was acquired by Cardiome Pharma Corp. (NASDAQ: CRME) in November 2013.